On January 11, 2017, BML Capital Management, LLC. announced that on January 9, 2017, ProPhase Labs, Inc. announced an agreement to sell the Cold-EEZE brand to Mylan for $50 million. BML Capital expressed its view that the price for the Cold-EEZE brand is fair and that the Board and management did a good job of monetizing the Company’s main asset. In addition, BML Capital expressed it concerns that the $50 million received would not flow through to shareholders. BML Capital stated that alternatively, if the entire Company had been sold for $50 million, which would include additional valuable assets such as an owned FDA approved manufacturing facility, owned headquarters building, and dietary supplement products, shareholders would receive $2.92 per share. BML Capital continued that this is nearly 40% more than the closing share price on January 10, 2017, the day after the transaction was announced. In addition, BML Capital stated that absent a formal agreement to provide liquidity to minority holders, or a change in the structure of the deal, BML Capital is concerned that minority holders will be left with an illiquid stock representing ownership of a money-losing business.